Introduction
Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder afflicting young children. [1] [2] [3] Recent studies elucidate the importance of the RAS-RAF-MAP (mitogenactivated protein) kinase signaling pathway, which is pathologically activated by mutations in RAS, PTPN11, and the gene encoding neurofibromatosis type 1 (NF1). [4] [5] [6] Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative strategy for children with JMML and it is recommended early in the course of the disease. Recent large studies indicate an eventfree survival of about 50% following HSCT in JMML. 7, 8 Despite the improvement in survival rate, relapse remains the major obstacle and the most common cause of treatment failure, affecting one-third of patients. 7 It occurs early, at a median of 2-6 months from transplantation, 9, 10 and generally within the first year following HSCT.
Donor leukocyte infusion (DLI) has been administered to patients who suffered a relapse following HSCT for various hematological malignancies. The efficacy of DLI depends on several factors including the sensitivity of the underlying disorder to a graft-versus-leukemia (GVL) effect. In JMML, the role of DLI for the management of recurrent disease remains uncertain; only a few relapsed patients successfully treated by DLI have been reported. [11] [12] [13] [14] In this study, we summarize the experience with DLI in 21 children with JMML, enrolled in studies of the European Working Group of MDS in Childhood (EWOG-MDS), and relapsed after allogeneic HSCT.
Patients and methods
In all, 21 patients with JMML transplanted from June 1996 to August 2002 received DLI from their original donor for mixed chimerism (MC) or relapse after first (n ¼ 17) or second (n ¼ 4) HSCT for JMML. The patients had been transplanted in 14 centers in Germany (n ¼ 11), Austria (n ¼ 4), the Czech Republic (n ¼ 2), the Netherlands (n ¼ 2), Denmark (n ¼ 1), and Italy (n ¼ 1). Data on administration and response to DLI, chimerism analyses, and therapy other than DLI were retrospectively collected by a standardized questionnaire in August 2003. Details on one patient (A014) have been reported previously.
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Informed parental consent for participation in EWOG-MDS studies had been obtained for all patients. The median follow-up period was 18 months (range 0.9-78) after DLI.
Patient characteristics
The median age at the time of diagnosis of JMML was 35 months (Table 1) . Chromosomal analyses of leukemic cells showed monosomy 7 in two patients, other abnormalities in four, and a normal karyotype in 15 children. A clinical diagnosis of NF1 was made in two patients. In total, 10 patients had been splenectomized prior to first (n ¼ 9) or second (n ¼ 1) HSCT. PTPN11 and RAS mutations were examined as previously reported 4, 6 in 17 children. At the time of first HSCT, all patients had active disease with a median blast count in the bone marrow (BM) of 15% (1-85).
Transplant procedure
The transplant procedure is detailed in Table 2 . The donor was an HLA-matched or -mismatched family member in nine cases, while 12 patients received a graft from an unrelated donor (UD). All but one patient who were given DLI after their first HSCT received a preparative regimen consisting of busulfan (BU) 4 mg/ kg/day for 4 days, cyclophosphamide (CY) 60 mg/kg/day for 2 days, and melphalan 140 mg/m 2 /day for 1 day, as described previously 7 ( Table 2 ). The patient transplanted from his haploidentical father was given CY 60 mg/kg/day for 2 days and thiotepa 10 mg/kg/day for 1 day. The preparative regimen of the first HSCT for the four patients who received DLI after the second HSCT included BU in three and total body irradiation (TBI) in one. For the second grafting procedure, the four patients received a pretransplant therapy including CY 60 mg/kg/day for 2 days and fludarabine 40 mg/m 2 /day for 5 days (n ¼ 1), BU 4 mg/kg/day for 4 days and melphalan 140 mg/m 2 /day for 1 day (n ¼ 1), and CY 60 mg/kg/day for 2 days and TBI 14.4 Gy (n ¼ 1), and CY 60 mg/kg/day for 2 days and thiotepa 10 mg/kg/day for 1 day (n ¼ 1). Source of stem cells was BM or cord blood in all patients transplanted from an HLA-matched sibling, while six of the remaining 15 patients received peripheral blood (PB) stem cells. Four patients, one transplanted from his haplo-identical father and three from a matched UD, received a T-cell-depleted graft.
Chimerism analyses
Chimerism analyses using unseparated PB or BM were performed by a microsatellite PCR system in 19 patients in six different laboratories [15] [16] [17] [18] [19] [20] and by FISH analysis in two patients with a sex-disparate donor. Analyses were performed at regular intervals after HSCT in 18 patients (weekly: n ¼ 11; every 1-3 months: n ¼ 7). In three patients, the first chimerism analysis was performed at the time of hematological relapse.
Definition
Engraftment after HSCT was defined by leukocytes 41 Â 10 9 /l in PB. Hematological relapse was diagnosed in the presence of an increased number of blast cells in PB or BM, or clinical signs of relapse with BM hypercellularity or absence of megakaryocytes. Acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) were diagnosed and scored according to standard clinical criteria. 21, 22 Patients were considered evaluable for aGVHD and cGVHD as a complication of DLI if they survived for 30 and 100 days post-DLI, respectively. Administration of DLI on multiple occasions less than 7 days apart was analyzed as one infusion. Complete response (CR) following DLI was defined by achievement of persistent complete chimerism (CC), without evidence of relapse. BM aplasia following DLI was defined as cytopenia 
Other (n ¼ 15)
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Statistics
The Fisher's exact test was used to examine the statistical significance of a relationship between the response to DLI and categorized factors. 23 A nonparametric rank test (MannWhitney U-test) was performed to evaluate the difference between responses to DLI in quantitative factors. 24 P-values less than 0.05 were considered to indicate statistical significance, whereas values greater than 0.05 were reported as nonsignificant (NS).
Results

Disease status and chimerism at DLI
All patients had achieved stable engraftment after the HSCT that preceded DLI. The median time to engraftment was 17 days. aGVHD Xgrade II had developed in five patients after the allograft, while no patient had suffered cGVHD.
The median time from HSCT to MC and from MC to first DLI was 160 days (14-793) and 57 days (4-225), respectively. At first DLI, seven patients had neither clinical nor cytogenetic signs of relapse. For the 14 patients with hematological (n ¼ 13) or cytogenetic (n ¼ 1) relapse prior to first DLI median time between relapse and DLI was 15 days (1-57). The percentage of autologous cells at first DLI varied between 3 and 100% (median 40) in PB (n ¼ 19) and between 15 and 90 % (median 48) in BM (n ¼ 8). For the six patients in whom data on MC in both PB and BM at first DLI were available, the percentage of autologous cells was comparable in both tissues, with the exception of one patient who had 60 and 90% autologous cells in PB and BM, respectively.
Procedure of DLI
Five patients received a single DLI, and 16 patients were given two to six infusions (median 3). The number of infused cells was reported as CD3 þ T-cell dose in 18 patients and as mononuclear cell (MNCs) dose in three patients. In the 18 evaluable patients, the number of CD3 þ T cells given with each infusion varied from 1 Â 10 4 to 2.4 Â 10 8 /kg, and the total number of T cells administered ranged from 9 Â 10 4 to 2.4 Â 10 8 /kg. Cyclosporine A (CSA) had been stopped prior to DLI in all patients. None of the patients had received chemotherapy between engraftment and administration of DLI. Three patients were given chemotherapy with 6-mercaptopurine (6-MP)7 cytosine arabinoside or thioguanine within 1 month following DLI. Another six patients received chemotherapy and/or cytokine treatment including interferon-alpha more than 1 month after DLI because of disease progression.
One patient (CZ019) was given DLI after the second relapse following HSCT. This patient developed MC on day 73 after HSCT. On day 82, hematological relapse with 52% blasts in BM and an abnormal karyotope 44-45, XY, der(5)t(5;17)del(11)(p) was diagnosed. Following the withdrawal of immunosuppressive agents (CSA, mycophenolate mofetil, steroids) and initiation of 6-MP therapy, the patient achieved CR on day 108. However, he suffered MC and cytogenetic relapse occurring on day 353, after which DLI was given on day 368. DLI in children with JMML relapsing after HSCT A Yoshimi et al
Response to DLI
Six of 21 patients responded to DLI and achieved CC at a median of 45 days (7-56) after DLI ( Table 3 ). The analysis of factors with possible influence on response to DLI is shown in Tables 4 and 5 . Response was observed irrespectively of karyotype, but the response rate in patients with abnormal karyotype was higher than in patients with normal karyotype. Although the number of patients is small, it is notable that none of the patients grafted and given DLI from a matched sibling donor achieved CC. The responding patients had received DLI from a matched cousin (n ¼ 1) or matched (6/6, n ¼ 4) and mismatched (5/6, n ¼ 1) UD.
Of the seven patients who had MC but no clinical signs of hematological relapse at the start of DLI, three achieved CC. One of these (CZ034) achieved CC after the first DLI with 1x10 6 / kg T cells (Table 3 ). However, 6 days before DLI, CSA had been stopped. The patient suffered hematological relapse 26 days after the first DLI and did not respond to the second DLI with 1 Â 10 7 /kg T cells. Thus, withdrawal of immunosuppressive therapy might have contributed to the response noted after the first DLI. The other two patients did not respond to the first DLI, progressed to hematological relapse and achieved CC after the second DLI (Table 3) . Three of 14 patients with hematological relapse at first DLI achieved CC and CR after a single infusion of more that 1 Â 10 7 /T cells/kg (Table 3 ). Except patient CZ034 described above, no other patient who received less than 1 Â 10 7 /kg T cells responded. Only one of the six responding patients had received concomitant chemotherapy; this patient was given 6-MP for 30 days between the second and third DLI.
Complications after DLI
Complications after DLI were observed in six of six responding and one of 15 nonresponding patients. In four of the six responders, aGVHD (grade II: n ¼ 2; grade IV: n ¼ 2) was diagnosed 4-40 days after the initiation of DLI. Steroid and/or CSA were given in these patients. Grade IV aGVHD was treated intensively with additional high-dose steroid, ATG or OKT3, although it was fatal in one patient. One nonresponder developed aGVHD grade II 20 days after the last of six DLI administered between days 47 and 167 post-HSCT. cGVHD developed in two of 16 evaluable patients. Both patients were responders and had received a single dose of DLI. One of those developed cGVHD 349 days after DLI and following aGVHD, the other suffered de novo cGVHD 275 days after DLI. Complications other than GVHD were seen in two responders; fatal BM failure diagnosed 26 days after DLI in one and a hypereosinophilic syndrome (HES) successfully treated with steroid in another. In total, two patients, all responders, succumbed to complications of DLI.
Clinical course and outcome
Of the six patients who responded to DLI, one patient is alive in CR with persistent CC 72 months after DLI. This patient is suffering from extensive de novo cGVHD. Two responding patients experienced a subsequent hematological relapse, one 54 months after DLI as gastric chloroma and the other patient (CZ034) is alive in CR after a second HSCT. 
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Of the 17 patients suffering progression of disease after DLI, seven underwent a second HSCT. Prior to second HSCT, six patients received none or low-dose chemotherapy; the only patient given AML-like therapy did not achieve CR. The median time from first HSCT, first DLI and last DLI to second HSCT was 401 days (162-907), 105 days (43-153), and 87 days (43-153), respectively. The preparative regimen for second HSCT following DLI included TBI in all patients. One patient was transplanted from the twin sister of the original UD; all other patients received a graft from the original donor. Intensity of GVHD prophylaxis was reduced compared to the first HSCT in five patients. aGVHD (Xgrade II) and cGVHD were observed in five and two patients after second SCT, respectively. Five of the seven patients who have undergone a second transplant procedure for disease progression after DLI are alive in CR with a median follow-up of 13 months (4-74) after second HSCT.
Discussion
Treatment options for patients relapsing with leukemia after HSCT are limited. Withdrawal of immunosuppressive drugs is usually the first measure, which by itself can control leukemia in a limited number of patients. Several reports [25] [26] [27] [28] [29] [30] and the clinical course of patient CZ019 in this series indicate the efficacy of withdrawal of immunosuppressive therapy in some patients with relapsed JMML, suggesting a GVL effect in JMML. In the case of nonresponse and for patients suffering disease recurrence after discontinuation of immunosuppressive agents, DLI or second HSCT may be considered.
Matthes-Martin et al 11 reported the first case of JMML with monosomy 7 successfully treated with DLI. MC and monosomy 7 were detected in PB 14 days prior to DLI and morphology of BM on the day of DLI was suggestive of relapse. The patient is alive in CR 73 months after DLI. However, a subsequent retrospective analysis demonstrated CC in CD34
þ positive cells at the initiation of DLI in this patient (S Matthes-Martin, personal communication, November 2004). As the effect of DLI is difficult to evaluate in this situation, we excluded the patient from this study. In the literature, there are three other cases of successful therapy with DLI of relapsed JMML. [12] [13] [14] Two of the three patients had a normal karyotype, and one monosomy 7. Following chemotherapy (n ¼ 2) or splenectomy (n ¼ 1), DLI from the matched (n ¼ 2) or one HLA locus mismatched (n ¼ 1) UD were administered. GVHD was observed in two patients, BM failure in one, and all patients were alive at the time of reporting. These case reports suggest that at least some relapsed JMML patients can benefit from DLI. However, the overall efficacy of DLI in relapsed JMML is unknown; reporting bias is likely to exaggerate the benefit of this form of therapy in single successful cases. In this multicenter retrospective study of 21 children given DLI for MC or hematological relapse following HSCT for JMML, six patients responded and achieved CC. While three responders died due to complications and two subsequently relapsed, one patient remains in CR with extensive cGVHD.
Several factors correlated with response to DLI in our study. First, the T-cell dose had a significant impact on response to DLI. None of the eight patients who received a total T-cell dose o1 Â 10 7 /kg showed a sustained response. In the previously published reports detailed above, [12] [13] [14] the JMML patient given DLI from a mismatched UD responded to 1 Â 10 6 /kg T cells, the other two patients were given 1x10 7 /kg or 1x10 8 /kg T cells from a matched UD. Although we cannot draw definite conclusions due to the small number of patients, we suggest that at least 1 Â 10 7 /kg T cells are necessary for response to DLI in JMML, except for cases with HLA-mismatched donors. Second, the response rate to DLI was significantly higher when leukemic cells harbored an abnormal karyotype (Table 3) . Worth et al 12 had already hypothesized that JMML cells with monosomy 7 may be more sensitive to DLI. Patients with monosomy 7 may represent a subset of patients with different biology, although studies showed the cytogenetic abnormalities including monosomy 7 are not predictive of outcome after first HSCT. 7, 31 Third, consistent with previous reports in CML, 32, 33 occurrence of GVHD correlated with response to DLI, suggesting a substantial overlap between the GVL effect and GVHD occurrence. It is also noteworthy that in this series of JMML, none of the patients given DLI from a matched sibling donor responded. Moreover, in all the three previously reported JMML patients successfully treated by DLI, the donor was an unrelated volunteer. [12] [13] [14] In contrast, in CML, there is no apparent major difference in efficacy of DLI in patients receiving lymphocytes from an HLAmatched sibling compared to a matched UD. 32, 34, 35 Modifications of the procedure will be needed for DLI from a matched sibling in JMML. Recombinant interleukin-2 increases the response rate with improved survival in a proportion of patients with other leukemias who relapse after HSCT and do not respond well to DLI alone. It may be worth to evaluate IL-2 as adjuvant therapy in conjunction with DLI in JMML. 36, 37 Both disease burden and phase of disease have a strong impact on response to DLI, as shown by the high success rate of cellular therapy implemented early in the course of recurrent CML. 32, 33, 38 In CML, early intervention is feasible because the bcr-abl gene serves as a molecular marker for the detection of minimal residual disease (MRD). In JMML, like in some other leukemias, disease-specific markers for MRD are not available and therapeutic interventions will be based on sequential chimerism studies. In JMML (Yoshimi A et al. Blood 2003; 102: 706, abstract), patients with persistent MC have a high risk of relapse. 39, 40 In fact, in this study, all patients with MC experienced a hematological relapse. However, possibly due to the poor overall response rate to DLI, we were unable to demonstrate a higher success rate in cases of early intervention. Several studies are currently investigating whether cytoreduction prior to DLI is advisable for leukemia patients with a high disease burden. Previous reports suggested a role of chemotherapy-induced cytoreduction or cytokine treatment with interferon-alpha along with DLI in JMML. 13, 14 As none of the patients studied here received chemotherapy or splenectomy between last SCT and initiation of DLI, we cannot comment on the efficacy of this strategy in JMML. Like the use of cytokines, the role of cytoreduction with chemotherapy or novel drugs such as E21R 41 will have to be studied in well-designed clinical trials of cellular therapy in relapsed JMML.
Second HSCT is another treatment option for patients experiencing relapse after an allograft. In this study, seven patients, six nonresponders and one responder with recurrent disease after DLI, underwent a second HSCT. Five of these seven patients are alive in CR. This surprisingly favorable outcome after second HSCT even with the same donor might be explained by difference in the preparative regimen, reduced GVHD prophylaxis, and increased aGVHD and cGVHD following the second graft.
In conclusion, this study shows that JMML can be sensitive to DLI, providing evidence for a GVL effect also in this malignancy. Response to DLI requires a critical number of T cells and correlates with a high risk of GVHD. However, due to complications and relapse, the overall outcome of patients responding to DLI was poor. It is currently unknown whether DLI or early second HSCT should be favored as a rescue treatment for children with JMML relapsing after a first grafting procedure. The results of DLI might be improved by modifications, such as the administration of adequate number of T cells, use of chemotherapy, or of concomitant cytokines. On the other hand, by overestimating the effect of DLI in relapsed JMML the opportunity for a second HSCT might be missed.
